There exist several extensive tabulations of EPs in the literature, measured from excised normal 2,29-32 and malignant 3,33-36 tissues. Systematic studies comparing these with in vivo EPT measurements are relatively scarce, sometimes with conflicting results. Table 1 provides an illustrative
| INTRODUCTION
The tissue's dielectric permittivity (ε) and conductivity (σ) (electrical properties [EPs] ) measure, respectively, the polarization and current densities induced by an applied electric field of unit amplitude. 1 Their magnitudes are dictated by water content, cell shape and size, and location/mobility of ions and cell membranes. 1, 2 For a given tissue, they vary within subjects, between subjects, and with pathological conditions. 2,3 MRI, which relies on RF magnetic fields (B 1 ) to generate and measure the signal, has been an early candidate for tissue EP measurement, with a relevant publication appearing as early as in 1991. 4 Following brief activities in 2003 and 2006, 5, 6 3 independent groups in 2009 revisited and advanced the concept of reconstructing EPs from the B 1 maps (called electrical properties tomography, or EPT). [7] [8] [9] This sparked a flurry of activities in reconstruction algorithm development, [10] [11] [12] [13] [14] [15] [16] [17] validations in healthy subjects 18, 19 and patients, [20] [21] [22] and comparative analyses of EPs versus other quantitative MRI measures. 23, 24 Although comprehensive overviews of EPT methodologies already exist, [25] [26] [27] [28] less attention was paid to understanding the capabilities of available reconstruction algorithms in relation to the EP contrasts and their variability existent in vivo. Acknowledging the rapidly evolving EPT research landscape, this review intends to parallel the existing contrast in the tissue's EPs with the capabilities of the most commonly used in vivo EPT methodology at clinical field strengths, with a hope to provide a reference for continued development of EPT toward more impactful clinical translation. 2. The large variability in the normal tissue-cancer contrast is in part due to how normal tissue is defined in various studies.
• In the case of breast, multiple reports defined normal mammary tissue (inadvertently) as predominantly adipose. 3, 33, 34 Focusing on the more clinically relevant comparison of cancer with contrast-enhancing fibroglandular tissue, it is found that their distinction is not trivial by conductivity measurement; carefully crafted in vitro studies indicated only about 25% differences between these 2 tissue types. 35 A different report, focusing on larger breast tumors (which may skew results), indicated a more optimistic ~100% available contrast. 22 • For brain, conductivities of large tumors are often compared to normal white matter conductivity, indicating 60% to 120% contrast. 21, 37 Tumor conductivities, however, only approached normal gray matter conductivity, 18 implying potentially weak contrast for tumors at the white-gray matter boundaries.
A few studies reported inter-and intraperson variability in normal tissue, indicating differences on the order of 7% to 20% that are unrelated to disease processes. 3, 22, 38 Moreover, it is found that conductivity contrast between normal and cancerous tissue remains roughly constant between 1.5 T and 7 T, whereas permittivity contrast decreases from 1.5 T to 7 T. 23, 39 From the limited studies available on EP changes in cancer, many cancer types outside the brain and breast appear to exhibit less than 40% changes in EPs. This imposes a lower bound for the SNR (defined as r ∕Δ r or ∕Δ , where r is the relative permittivity and Δ denotes measurement uncertainty) of EPT for its clinical utilization. As an illustration, assume that the mean normal tissue conductivity or permittivity has historically been determined to be m. To determine if a prospective measurement, X, is higher than m with 95% confidence, a Z score ((X − m)∕s) of 1.65 is needed 40 ; here s is the standard deviation of the measurement. Figure 1 displays the SNR needed as a function of the ratio between the current measurement and historical mean, SNR = X∕s= 1.65X∕(X − m). Although an SNR of 5 is sufficient to detect 50% changes, an SNR of ~18 is needed for 10% changes to be detected. The method is based on rearrangement of the Helmholtz equation applied to transmit or receive B 1 in a piecewise-homogeneous medium:
| Capabilities of Helmholtz-based EPT
where is the magnetic permeability; 0 is the vacuum permittivity; and = 2 f is the Larmor frequency. Ignoring boundary artifacts and tissue heterogeneity, the SNR behavior of Helmholtz-based EPT has been theoretically analyzed 47 ; the main results are.
(1) The SNR of permittivity/conductivity is proportional to the EPs themselves and depends quadratically/linearly on . In addition, it is proportional to the SNR of the B 1 map, the square root of the number of voxels (N tot ) in the region of interest (ROI), and the square of the ROI size (L). The numerical factor G depends on the ROI shape, being about 91 for a sphere. Rapid decrease of SNR with shrinking ROI size, implied by Equations 3 and 4, presents a challenge for the spatial resolution of conventional EPT. For a gray matter, 2 cm-diameter spherical ROI, and an input B 1 SNR of 100 (at the high end of what is achievable in vivo 19 ), the conductivity and permittivity SNR at 1.5/3/7 T has been calculated to be on the order of 4/8/22 and 2/7/32, respectively 47 ( Figure 1 ). It should be noted that although theoretical random noise-dominated SNR clearly favors high field strengths, Helmholtzbased EPT at 7 T has been shown to suffer from increased systematic reconstruction errors. 48 Furthermore, permittivity contrast between normal and cancerous tissues may diminish at 7 T.
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| Clinical applications
There are many conference abstracts reporting proof-ofconcept EPT results in a few patients or normal volunteers 20, 43, 45, 46, [49] [50] [51] ; however, few advanced to properly documented journal publications examining wider clinical cohorts and utility. Notable exceptions are the summary of conductivities of 30 glioma patients, 52 reports on conductivities of normal and cancerous breast tissue and correlations with prognostic factors 22, 53 (n = 90 and 65, respectively), and studies investigating conductivities of cervical tumors and the impact of individualized EP measurements on hyperthermia treatment planning 38, 54 (n = 20 and 5, respectively). The variability and uncertainty of EPs obtained from existing EPT methods can be appreciated from Table 1 . In addition, the following observations can be made from these studies:
1. EPT-measured conductivities of cancerous tissues are larger than those of normal tissues in the literature, by about 10% (cervical cancer), 38 100% (breast cancer against normal fibroglandular tissue), 22 and 70% to 100%
(gliomas against normal white matter). 
2.
Results on in vivo permittivity by EPT are rare and have large error bars at low (1.5 T) field strengths. 4. Whereas in one of the studies tumor size had no effect on measured conductivity, 22 another discovered that correlations identified between prognostic factors and lesion size in the ≥2 cm tumors did not hold in the 1~2 cm tumors. 53 Although this may be due to the inherent pathology differences between smaller and larger tumors, it may also reflect the larger inaccuracy in determining EPs over smaller ROIs.
These observations are generally consistent with the reconstruction capabilities mentioned in the previous section, namely low intrinsic SNR of conventional EPT for small ROI sizes and at low fields. We conclude that some applications, in which large-region average EPs serve as additional lesion characterization features, can realistically benefit from current EPT techniques. On the other hand, many clinical applications requiring mm-range resolution for EP maps call for improved reconstruction capabilities.
| Alternative reconstructions
Recently proposed, novel EPT algorithms typically aim to remove simplifying assumptions of standard EPT, namely piecewise constant EPs and transceive phase assumptions, which introduce systematic errors near tissue boundaries 55, 56 and at high field strengths, 48 respectively. The phase assumption is commonly tackled with the use of multiple transmit and/or receive coils, [10] [11] [12] 57, 58 although certain variations of standard EPT are also capable of replacing this assumption with a different one. 59 The piecewise constant EP requirements are avoided by maintaining spatially dependent EP terms in reformulated EPT equation 60 ; examples include gradient-based EPT, 16 convection-reaction equation EPT, 13 and local Maxwell tomography. 10 Most of these alternative methods were unfortunately only demonstrated through simulations and phantom experiments 10, 13, 44, 58, 60 or in normal brain from a limited number of subjects. 12, 16 From the theoretical point of view, one potential issue for many of the newer methods is that the MR-invisible B z component of the RF field is ignored, an approximation that may not hold for all RF coil geometries. On the positive side, the EP SNR of global methods (eg, convection-reaction equation EPT) and local-global hybrid methods (eg, gradient-based EPT) appears generally higher than that of local methods (eg, Helmholtz-based), 27, 61 increasing the chances for clinical utilization. For most new methods, however, theoretical analysis of SNR analogous to Equations 3 and 4 and systematic studies of contrast capabilities have yet to be done. Another trend in alternative EPT concerns replacing direct EP computation from the measured fields with an inverse approach in which the measured data is fitted to forward-calculated fields from estimated EPs. Through iterative minimization of the cost function, which can include data consistency and regularization terms, one arrives at the best match without differentiating the measured data and amplifying noise in the process. A few of the relevant references are Refs. 14, 17, and 62 through 64; as above, however, the theoretical concepts are only presented mathematically, 62 
